-
About CPhI & P-MEC China Virtual Expo Connect
Market news
PharmaSources.comMay 07, 2020
Boost your business online @ CPhI & P-MEC China Virtual Expo Connect For the first time ever, CPhI & P-MEC China will embrace virtual technology in order to quickly adapt to market changes and needs.
-
Preliminary study of 300+ COVID-19 patients suggests convalescent plasma therapy effective
Market news
worldpharmanewsAugust 14, 2020
A preliminary analysis of an ongoing study of more than 300 COVID-19 patients treated with convalescent plasma therapy at Houston Methodist suggests the treatment is safe and effective.
-
SAB begins phase 1 trial of Covid-19 therapeutic candidate SAB-185
Market news
pharmaceutical-business-reviewAugust 14, 2020
SAB Biotherapeutics, a US-based clinical-stage company, has dosed the first participant of a phase 1 study of SAB-185, its therapeutic candidate for Covid-19, in healthy volunteers.
-
Celleron picks up discarded cancer drug from Roche
Market news
pharmatimesAugust 14, 2020
Oxford, UK-based Celleron Therapeutics has signed a licensing agreement with Roche for exclusive rights to emactuzumab, a monoclonal antibody and tumour microenvironment modulator.
-
F2G raises $60.8m to support late-stage antifungal clinical programme
Market news
pharmatimesAugust 14, 2020
UK-Austria-based biotech F2G has secured $60.8m in a new financing round to support late-stage development of a novel antifungal agent.
-
RedHill and Cosmo Pharmaceuticals Expand Strategic Partnership
Market news
contractpharmaAugust 14, 2020
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has entered into a binding term sheet with Cosmo Pharmaceuticals N.V. for an exclusive licensing and manufacturing agreement for multiple products.
-
ANA Therapeutics Partners with Quotient Sciences
Market news
contractpharmaAugust 14, 2020
Will manufacture ANA001 as a potential treatment for COVID-19.
-
FDA accepts application for self-administered Xolair use
Market news
pharmatimesAugust 14, 2020
The US Food and Drug Administration (FDA) has accepted Roche’s application for a new self-administration option for Xolair (omalizumab) across all approved US indications.
-
Seelos Receives FDA May Proceed Notice to Initiate a Trial of SLS-005 in ALS
Market news
americanpharmaceuticalreviewAugust 14, 2020
Seelos Therapeutics received notice from the Food and Drug Administration (FDA) that the company may proceed with initiating a Phase IIb/III trial studying SLS-005 (trehalose) for the treatment of Amyotrophic lateral sclerosis ...
-
Protalix BioTherapeutics, Chiesi Global Announce BLA Acceptance of Pegunigalsidase Alfa
Market news
americanpharmaceuticalreviewAugust 14, 2020
Protalix BioTherapeutics together with its development and commercialization partner Chiesi Global Rare Diseases, a unit of Chiesi, announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted ...
Pharma Sources Insight